antigen targeting Articles
-
A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity
Self-amplifying RNA vaccines may induce equivalent or more potent immune responses at lower doses compared to non-repli- cating mRNA vaccines via amplified antigen expression. In this paper, we demonstrate that 1 mg of an LNP-formulated dual- antigen self-amplifying RNA vaccine (ZIP1642), encoding both the S-RBD and N antigen, elicits considerably higher neutral- izing antibody titers against ...
-
Measurement of Heparin Dependent Antibodies with Immunoassays
Immunoassays for heparin dependent antibodies have been introduced since the discovery of PF4 as the major target antigen in presence of heparin. Different immunoassay presentations are available, and interestingly heparin can be replaced by polyanions complexes and its native structure is then altered as shown on figure 3. This alteration exposes PF4 epitopes, characteristic of the ...
-
Antibody Selection for ADC Drugs
Antibodies are the precise guidance components of ADCs. In theory, molecules that bring effector molecules to the surface of tumor cells can play the role of antibody guidance The choice of antibody for ADC drugs depends on the target of the disease. Targets can be divided into tumor-specific antigens (TSA) and tumor-associated antigens (TAA) according to their expression. Antigens that are only ...
By BOC Sciences
-
Antibody Drug Conjugates: "Biological Missiles" For Targeting Cancer Therapy
Antibody-drug conjugates (ADCs) usually consist of monoclonal antibodies (mAbs) covalently linked to cytotoxic drugs via chemical linkers. With high specific targeting ability and strong killing effect, it has achieved precise and efficient removal of cancer cells, and has become one of the hot spots in the development of anticancer drugs. In 2000, the FDA first approved the ADC drug Mylotarg ...
-
Optimization of Three Elements of ADC Drugs
Structurally, an ADC consists of monoclonal antibodies (Antibody) that target specific antigens on tumor surfaces, cytotoxic drugs (drugs) that kill tumor cells, and linkers (Conjugate/ linkers) that conjugate cytotoxic drugs to antibodies. The link between the antibody and linker is controlled by the coupling method, which determines the DAR value of the drug and affects the stability and PK ...
-
Design and analysis of nanowire sensor array for prostate cancer detection
Prostate cancer is one of the major cancer affecting men in India. After lung cancer, prostate cancer has caused large number of deaths in India. Nanowire is the biosensor used for detection of cancer. In this paper, we present a design of nanowire array sensor for prostate cancer detection. A sensor array of 8 × 8 elements is designed to capture the PSA present in the blood that helps in ...
-
Possible treatment of human multiple myeloma found
Multiple myeloma is an essentially incurable plasma cell cancer with a very poor prognosis for patients; however, in a recent study published in Science Translational Medicine entitled "Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the protein CD98 heavy chain," scientists from Osaka University in Japan have discovered the CD98 heavy chain, a common ...
By Profacgen
-
Three generations of ADC: Nearly a decade of development-PI
Antibody-drug conjugate (ADC), a compound that connects a cytotoxic small-molecule drug to a monoclonal antibody via a rationally established linker, which selectively delivers an efficient cytotoxic agent into the tumor, has made significant progress in the previous decade. The first ADC drug approved by the US FDA was gemtuzumab ozogamicin (Mylotarg) in 2009. Currently, the FDA has authorized ...
-
Antibody-Drug Conjugates For The Treatment of Prostate Cancer
Currently, ADC has played a significant role in the treatment of some malignant tumors, such as trastuzumab in the treatment of breast cancer, but its application in the treatment of prostate cancer (PCa) progress slowly. In recent years, ADC has made rapid progress in the treatment of metastatic castration-resistant prostate cancer (mCRPC). STEAP1, TROP2, PSMA, CD46, and B7-H3 are currently ...
-
Pathogenicity of Heparin Dependent Antibodies
Many of the heparin dependent antibodies, including those with the IgG isotype, are asymptomatic, and only a subgroup of antibodies is positive in platelet activation assays. What differentiates pathogenic from asymptomatic antibodies is not fully understood, with the exception that there is some relationship between antibody concentration and occurrence of HIT, and that antibodies with the ...
-
Science: Knockout of this epigenetic gene gives CAR-T cells the ability to continuously attack cancer cells
Simply put, CAR-T is to transform the patient's immune T cells in vitro by biotechnology, so that they recognize antigens on the surface of tumor cells, and then inject these cells back into the patient to achieve the therapeutic effect of recognizing and killing cancer cells. In 2017, CAR-T therapy was first approved by the FDA for the treatment of blood cancers such as leukemia and lymphoma. ...
-
Recombinant Cyno NKG2A & CD94 Heterodimer
Product name NKG2A and CD94 heterodimer (KLRC1), recombinant protein Full Product Name Recombinant human NKG2A and CD94 heterodimeric protein (N-8His and N-DYKDDDDK) Product synonym names Heterodimer NKG2A and CD94; Heterodimer KLRC1 and CD94; CD159A and KLRD1 heterodimer Product gene name Recombinant protein KLRC1 3D structure ModBase 3D Structure for P26715 Host: Human cells Purity ...
-
How to Design a Good ADC Drug
In the past ten years, the number of antibody drug conjugates (ADCs) entering clinical trials has steadily increased. Currently, 9 ADCs have been approved, of which 5 are used for hematoma and 4 for solid tumor treatment. After more than 20 years of development, ADC biopharmaceuticals are becoming the main force in the treatment of cancer. Currently, one of the most important challenges when ...
By BOC Sciences
-
ADC Cleavable Linker : Classification and Mechanism of Action
Antibody-drug conjugates (ADCs), as emerging anticancer drugs, can deliver highly cytotoxic molecules directly to cancer cells to kill them. ADC is a monoclonal antibody covalently bound to cytotoxic chemical substances (payload) through linker. ADC linker plays a key role in the therapeutic effect of ADC, and its characteristics greatly affect the therapeutic index, pharmacodynamics and ...
By BOC Sciences
-
Leishmaniasis Vaccine - Case Study
The World Health Organization in its report on Neglected Tropical Diseases has stated that there is overwhelming evidence to show that the burden caused by many of the 17 diseases that affect more than 1 billion people worldwide can be effectively controlled and, in many cases, eliminated or even eradicated. Leishmaniasis caused by Leishmania spp is one such example and poses a grave health risk ...
-
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly ...
-
CD Biosciences Launches Substrate-Chromogens for Immunohistochemistry
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technology, has announced the launch of its innovative line of Chromogenic Substrates for immunohistochemistry (IHC). These cutting-edge substrates offer superior signal sensitivity, long-term storage stability, enhanced safety, and user-friendliness, empowering researchers to unlock deeper insights into ...
-
Three generations of ADC: Nearly a decade of development-PII
Kadcyla and second-generation non-cleavable linkers Alternative linker design methodologies are still under development. Immunogen discovered a very powerful ADC by an accidental discovery. The lysine residue of trastuzumab is linked to DM1 via a non-cleavable linker containing N-succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), an ADC (T-DM1, Kadcyla) authorized by the FDA in ...
-
Characteristics and Applications of Luminex Multiplex Technology
Luminex multiplex assays is a multi-functional, multi-indicator parallel analysis system that organically integrates color-coded beads, laser technology, applied fluidics, the latest high-speed digital signal processor and computer algorithms to create a high degree of specificity and sensitivity for multi-factor detection. It can be widely used in immunoassay, nucleic acid research, enzymatic ...
-
Three generations of ADC Nearly a decade of development-PIII
Novel cytotoxic drugs New cytotoxic drugs have been developed to target cancer cells with low antigen expression or resistance to auristatins or maytansinoids. For this purpose, PBD dimers have been developed, which have a molecular structure containing two alkylated imine functional groups capable of forming covalent bonds with DNA.PBD dimers are about 50-100 times more potent than conventional ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you